Stocks and Investing Stocks and Investing
Wed, November 30, 2022
Tue, November 29, 2022

Tazeen Ahmad Maintained (SRPT) at Strong Buy with Increased Target to $138 on, Nov 29th, 2022


Published on 2024-10-28 00:21:55 - WOPRAI, Tazeen Ahmad
  Print publication without navigation


Tazeen Ahmad of B of A Securities, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $129 to $138 on, Nov 29th, 2022.

Tazeen has made no other calls on SRPT in the last 4 months.



There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 2 agree with Tazeen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $101 on, Thursday, November 3rd, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $141 on, Thursday, October 13th, 2022


These are the ratings of the 4 analyists that currently disagree with Tazeen


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $190 on, Thursday, November 3rd, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $158 on, Thursday, November 3rd, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $171 on, Thursday, November 3rd, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $145 on, Monday, October 17th, 2022
Contributing Sources